CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
MINGOdietary
Likely dose
MINGO 6 sachets (20 oz each) daily by mouthAI-extracted
Key inclusion· 4
  • ✓Age 18 or above
  • ✓Confirmed XDP diagnosis by movement disorder specialist or fellow
  • ✓Supportive home environment (affirmative response in most recent doctor's monthly report)
  • ✓Accessible to passable roads and public transportation
Key exclusion· 6
  • ✕Extreme involuntary movements that prevent BMI or MUAC measurement
  • ✕Abnormal metabolic laboratory results at baseline
  • ✕Currently taking pharmacological or medicinal supplements affecting weight
  • ✕Hospitalization within 2 weeks before trial start

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03019458
NCT03019458N/ACompleted
CompareCT.gov

MINGO Supplemental Trial in X-linked Dystonia Parkinsonism Patients: A Prospective Randomized, Open-labeled, Parallel Group Trial

Sunshine Care Foundation·interventional·Posted Jan 12, 2017·Updated Apr 30, 2020

In Brief

A clinical study evaluating MINGO for X-Linked Dystonia Parkinsonism. Completed, enrolled 50 participants across 1 site.

Detailed Summary

To see whether MINGO, a food supplement, will be able to lessen the drastic weight loss seen among X-linked Dystonia Parkinsonism patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsX-Linked Dystonia Parkinsonism
CountriesPhilippines
CollaboratorsJose R. Reyes Memorial Medical Center, Massachusetts General Hospital

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJan 12, 2017
Enrollment StartFeb 10, 2017
Primary CompletionMay 8, 2017
Study CompletionJun 26, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.5 years ago

Interventions

MINGOdietary

6 20oz sachets will be taken daily by intervention group